We could not find any results for:
Make sure your spelling is correct or try broadening your search.
BeiGene Ltd is a commercial-stage biotechnology company. It is engaged in the discovery and development of molecularly targeted and immuno-oncology drugs for the treatment of cancer. The company has developed a proprietary cancer biology platform that addresses the importance of tumor-immune system ... BeiGene Ltd is a commercial-stage biotechnology company. It is engaged in the discovery and development of molecularly targeted and immuno-oncology drugs for the treatment of cancer. The company has developed a proprietary cancer biology platform that addresses the importance of tumor-immune system interactions and the value of primary biopsies in developing new models to support its drug discovery effort. It has developed clinical-stage drug candidates that inhibit the important oncology targets Bruton's tyrosine kinase, or BTK; RAF dimer protein complex and PARP family of proteins, and an immuno-oncology agent that inhibits the immune checkpoint protein receptor PD-1. Its geographical segments are China, the United States, and the Rest of the world. Show more
グローバルに実施した、3相RATIONALE 302治験は、TEVIMBRAが以前に全身治療を受けた患者において、化学療法と比較して長い生存期間を示した 承認は、米国におけるTEVIMBRAの最初の適応となる (ビジネスワイヤ...
全球性三期RATIONALE 302臨床試驗表明,TEVIMBRA與化療相比可延長既往接受全身治療患者的生存期 本次獲批屬TEVIMBRA在美國的首個適應症 (美國商業資訊)-- 全球性腫瘤學企業百濟神州(納斯達克股票代碼:BGNE;...
Les résultats de l’essai mondial RATIONALE 302 de Phase 3 ont montré que TEVIMBRA a prolongé la survie des patients ayant déjà reçu un traitement systémique par rapport à la chimiothérapie...
Die Ergebnisse der globalen RATIONALE 302 Phase 3-Studie zeigten, dass TEVIMBRA das Überleben von Patienten, die zuvor eine systemische Behandlung erhalten hatten, im Vergleich zu einer...
Results from the global, Phase 3 RATIONALE 302 trial showed TEVIMBRA prolonged the survival of patients who received prior systemic treatment compared to chemotherapy Approval represents the...
低・中所得29か国のうち、アルメニアとネパールより投与を開始 (ビジネスワイヤ) -- 世界中の患者に医薬品、テクノロジー、支援サービスを提供することにより、健康の公平性促進に取り組む世界的な非営利組...
亞美尼亞和尼泊爾是29個接受BRUKINSA的國家中的首批國家 (美國商業資訊)-- 致力於透過向全球病患提供藥物、科技和支援性服務來加速實現健康公平的全球性非營利組織The Max Foundation (Max)、全球性腫瘤公司Bei...
L’Arménie et le Népal sont les premiers des 29 pays à recevoir BRUKINSA La Max Foundation (Max), une organisation mondiale à but non lucratif dont l’objectif est d’accélérer l’équité en matière...
Armenien und Nepal sind die ersten von 29 Ländern, die BRUKINSA erhalten Die Max Foundation (Max), eine weltweit tätige gemeinnützige Organisation, die sich für mehr Chancengleichheit im...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DR |
4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DR |
12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DR |
26 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DR |
52 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DR |
156 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DR |
260 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DR |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions